Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2012 by Jaruboot Angsanakul, Queen Saovabha Memorial Institute.
Recruitment status was: Not yet recruiting
Information provided by (Responsible Party):
Jaruboot Angsanakul, Queen Saovabha Memorial Institute
First received: May 16, 2012
Last updated: May 17, 2012
Last verified: May 2012
Prevalence of participants who have protective immunity to measles virus is less than ninety percent.
Predictor of adequate measles antibody levels include the following :
- History of measles infection
- History of complete measles primary immunization( 2 doses with at least 1 month interval after age of 9 months)
- History of measles exposure
Predictor of inadequate measles antibody levels include the following :
- Born outside Thailand
- History of staying outside Thailand for long time in childhood
- Living in the rural area for a long period in childhood
- Fail to participate school system on time
||Observational Model: Case Control
Time Perspective: Cross-Sectional
||Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors
Biospecimen Retention: Samples Without DNA
Each participant will be taken blood sample approximately 8 ml. The blood sample will be centrifuged and kept as serum. The serum will be kept under - 20 degree Celsius. Then, all serum will be tested by ELISA.
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||January 2013 (Final data collection date for primary outcome measure)
Adequate antimeales antibody levels
ELISA test OD > 0.1
Inadequate measles antibody levels
ELISA test OD < 0.1
|Ages Eligible for Study:
||18 Years to 30 Years (Adult)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Health Thai participant age 18-30 years old.
- Last measles vaccination less than 10 years of age
- Immunocompromised host including congenital immune defect, splenectomy or splenic dysfunction, history of suspect HIV exposure, taking immunosuppressant
- Receiving blood or blood product within 3 months
- Receiving others vaccinations or immunoglobulins or any medication that possibly decrease immune response
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01602094
|Queen Saovabha Memorial Institute
|Bangkok, Thailand, 10330 |
|Contact: Maneerat Benjavongkulchai, R.N. 662-252-0161-4 ext 124 email@example.com |
|Principal Investigator: Jaruboot Angsanakul, M.D. |
|Sub-Investigator: Maneerat Benjavongkulchai, R.N. |
Queen Saovabha Memorial Institute
||Jaruboot Angsanakul, M.D.
||Queen Saovabha Memorial Institute
||Jaruboot Angsanakul, Queen Saovabha Memorial Institute
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 16, 2012
||May 17, 2012
Keywords provided by Jaruboot Angsanakul, Queen Saovabha Memorial Institute:
Donor of National Blood Centre, The Thai Red Cross Society who age 18-30 years old
Measles antibody levels
Predictors of adequate measles antibody levels and inadequate measles antibody levels
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 25, 2017
RNA Virus Infections
Physiological Effects of Drugs